The Manufacturers Life Insurance Company Acquires 113,152 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

The Manufacturers Life Insurance Company lifted its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 113.8% in the second quarter, according to the company in its most recent filing with the SEC. The fund owned 212,581 shares of the biotechnology company’s stock after acquiring an additional 113,152 shares during the quarter. The Manufacturers Life Insurance Company owned 0.10% of BioCryst Pharmaceuticals worth $1,314,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the business. Xponance Inc. lifted its holdings in shares of BioCryst Pharmaceuticals by 13.1% in the 2nd quarter. Xponance Inc. now owns 12,980 shares of the biotechnology company’s stock worth $80,000 after acquiring an additional 1,505 shares during the last quarter. CWM LLC raised its holdings in BioCryst Pharmaceuticals by 200.0% during the 2nd quarter. CWM LLC now owns 5,658 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 3,772 shares during the last quarter. Diversified Trust Co raised its holdings in BioCryst Pharmaceuticals by 18.0% during the 2nd quarter. Diversified Trust Co now owns 24,752 shares of the biotechnology company’s stock valued at $153,000 after buying an additional 3,774 shares during the last quarter. ProShare Advisors LLC raised its holdings in BioCryst Pharmaceuticals by 9.1% during the 1st quarter. ProShare Advisors LLC now owns 48,503 shares of the biotechnology company’s stock valued at $246,000 after buying an additional 4,041 shares during the last quarter. Finally, Signaturefd LLC raised its holdings in BioCryst Pharmaceuticals by 560.5% during the 2nd quarter. Signaturefd LLC now owns 6,598 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 5,599 shares during the last quarter. 85.88% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on BCRX. Royal Bank of Canada reiterated an “outperform” rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, August 6th. JMP Securities upped their price target on shares of BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the company a “market outperform” rating in a report on Tuesday, August 6th. StockNews.com upgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, August 6th. Barclays boosted their price objective on shares of BioCryst Pharmaceuticals from $6.00 to $7.00 and gave the company an “equal weight” rating in a research report on Tuesday, August 6th. Finally, HC Wainwright reissued a “buy” rating and set a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, August 6th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, BioCryst Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $14.17.

BioCryst Pharmaceuticals Price Performance

NASDAQ:BCRX opened at $7.43 on Friday. BioCryst Pharmaceuticals, Inc. has a 1-year low of $4.03 and a 1-year high of $8.88. The firm’s 50-day moving average price is $7.83 and its 200-day moving average price is $6.58. The company has a market capitalization of $1.54 billion, a PE ratio of -10.18 and a beta of 1.88.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.11. The firm had revenue of $109.30 million for the quarter, compared to analysts’ expectations of $98.30 million. During the same period last year, the company posted ($0.24) earnings per share. The business’s revenue for the quarter was up 34.9% compared to the same quarter last year. Equities analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.38 EPS for the current fiscal year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.